Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 November 2024 – This...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 8 November 2024 – The execution of Novo Nordisk A/S’ overall share repurchase...
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme Bagsværd, Denmark, 8...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 November 2024 — This...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 November 2024 — This...
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 5 November 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase...
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial Bagsværd...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 21 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase...
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in...
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase...
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities The initiative will launch in six cities...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads